Commentary|Podcasts|August 3, 2023

Pharma Marketing in the Age of AI: A New Era Begins

This podcast companion to our roundtable feature explores the transformative power of AI in pharmaceutical marketing, six months after the arrival of ChatGPT.

In this podcast, Sharlene Jenner, vice president of engagement strategy at Abelson Taylor and professor of AI and personalization for digital marketers at Southern Methodist University, leads a panel of five industry leaders in a roundtable discussion. The conversation delves into the practicalities of current AI applications and confronts the ethical and regulatory issues related to thetechnology. The panelists also explore the direct consequences and prospective implications of AI, providing listeners with a snapshot of the present and an outlook on the transformative potential of emerging technologies in the pharmaceutical marketing sphere.

Sponsor

https://www.zs.com/

About the speakers

The moderator, Sharlene Jenner, is the vice president of engagement strategy, AbelsonTaylor, and professor, Southern Methodist University, artificial intelligence and personalization for digital marketers.

The panel consists of:

  • Faruk Capan, chief innovation officer, EVERSANA, and CEO, EVERSANA INTOUCH
  • Anurag Banerjee, CEO and founder, Quilt.AI
  • Jeff Headd, vice president, commercial data science, The Janssen Pharmaceutical Companies of Johnson & Johnson
  • Stephen Onikoro, senior principal, head of strategy, PharmaForceIQ

About the Pharm Exec Podcast

The editors of Pharmaceutical Executive brings you the latest commercial insights to master the science of success. Podcast episodes examine current trends, key conferences, and critical topics in the bio/pharmaceutical industry.

Listen to this podcast on SoundCloudSpotifyGoogle Podcasts, or Apple Podcasts.


Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Pharmaceutical Executive daily
FDA approves Kerendia as the first new treatment for kidney disease in type 1 diabetes in decades, Novo, Roche, and Aethlon Medical strike major deals and mergers with Orbis Medicines, Dualitas Therapeutics, and North Immunology, and Thani Jambulingam of Saint Joseph's University examines the fight to control the GLP-1 patient journey.
Pharmaceutical executive daily
GSK is acquiring a trispecific T-cell engager from Chimagen Biosciences and Sanofi expanding its manufacturing partnership with Cheplapharm, Stewart Gandolf discusses why pharma marketing now has to write for both people and AI, and Dr. Elena Christofides explains why cortisol dysregulation may be the hidden reason some diabetes patients fail to respond to incretin therapies.